Response to Reviewer 3 Comments

Recently, platelet has been found to play an active role in liver disease. From 2016 to 2019, there are some review articles discussing the relationship between platelet, cancer, liver fibrosis or chronic liver disease which highlights the importance of platelet in different aspects. In this review article, by understanding the mechanisms between platelets and HCC allows to provide a novel and valuable therapeutic approach in the future clinical treatment. I suggest that the author can address the following questions:

**Point 1:** The authors made too much segmentation in each section (especially in section 2, 3 and 4), it is hard to read. I suggest the author can merge some paragraph or giving the subtitle might also be a solution for better organized the paragraph.

**Response 1:**
We have merged several paragraphs in these sections.

**Point 2:** In section 5, the author is discussing the regulations between platelets and the hepatic immune response. Recently, there are an important finding of this topic that had been published in Nature Medicine this year. The article entitled “Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer.” From this research, they had found that platelet-mediated inflammation will cause NASH and carcinogenesis. The author should also include this new information in this review article.

**Response 2:**
Thank you for this very interesting reference, we have added it to several parts in the review article.

**Point 3:** In the article, the author has reported the target of platelets as a therapeutic approach in liver disease. However, since the chemotherapy is the main approach for the treatment of advanced HCC patients in the clinic, the author should also collect the relative researches to describe nowadays findings in the relationship of platelets and chemotherapy. For example, in article “Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines”, they had found that platelet inhibits the cytotoxicity of the chemotherapy drugs, sorafenib and regorafenib, in HCC.

**Response 3:**
Thank you for this interesting angle on therapeutic approach. We have now discussed this in the manuscript.

**Point 4:** There are some small errors in the manuscript, please check again carefully. For example, in line 30, there are two dots at the end of the sentence.

**Response 4:**
We carefully went through the manuscript to correct grammatical errors and spelling mistakes. We updated the style in several parts and removed repetitive use of certain words. We also removed the two dots in line 30, as well as other small errors.